SG11201808820QA - Methods and kits for the diagnosis and risk stratification of patients with ischemia - Google Patents

Methods and kits for the diagnosis and risk stratification of patients with ischemia

Info

Publication number
SG11201808820QA
SG11201808820QA SG11201808820QA SG11201808820QA SG11201808820QA SG 11201808820Q A SG11201808820Q A SG 11201808820QA SG 11201808820Q A SG11201808820Q A SG 11201808820QA SG 11201808820Q A SG11201808820Q A SG 11201808820QA SG 11201808820Q A SG11201808820Q A SG 11201808820QA
Authority
SG
Singapore
Prior art keywords
sant
international
ischemia
pavello
iccc
Prior art date
Application number
SG11201808820QA
Other languages
English (en)
Inventor
Maestro Lina Badimon
Ràfols Judit Cubedo
Capmany Teresa Padró
Original Assignee
Fundacio Inst De Recerca De L´Hospital De La Santa Creu I Sant Pau
Consejo Superior Investigacion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Inst De Recerca De L´Hospital De La Santa Creu I Sant Pau, Consejo Superior Investigacion filed Critical Fundacio Inst De Recerca De L´Hospital De La Santa Creu I Sant Pau
Publication of SG11201808820QA publication Critical patent/SG11201808820QA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11201808820QA 2016-04-12 2017-04-12 Methods and kits for the diagnosis and risk stratification of patients with ischemia SG11201808820QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382167.1A EP3232200A1 (en) 2016-04-12 2016-04-12 Methods and kits for the diagnosis and risk stratification of patients with ischemia
PCT/EP2017/058768 WO2017178521A1 (en) 2016-04-12 2017-04-12 Methods and kits for the diagnosis and risk stratification of patients with ischemia

Publications (1)

Publication Number Publication Date
SG11201808820QA true SG11201808820QA (en) 2018-11-29

Family

ID=56008566

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808820QA SG11201808820QA (en) 2016-04-12 2017-04-12 Methods and kits for the diagnosis and risk stratification of patients with ischemia

Country Status (15)

Country Link
US (1) US11486884B2 (cg-RX-API-DMAC7.html)
EP (2) EP3232200A1 (cg-RX-API-DMAC7.html)
JP (1) JP7075894B2 (cg-RX-API-DMAC7.html)
KR (1) KR102344344B1 (cg-RX-API-DMAC7.html)
CN (1) CN109154620B (cg-RX-API-DMAC7.html)
AU (1) AU2017251355A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018070971A2 (cg-RX-API-DMAC7.html)
CA (1) CA3020666A1 (cg-RX-API-DMAC7.html)
ES (1) ES2979390T3 (cg-RX-API-DMAC7.html)
IL (1) IL262245B (cg-RX-API-DMAC7.html)
MA (1) MA44658A (cg-RX-API-DMAC7.html)
MX (1) MX2018012580A (cg-RX-API-DMAC7.html)
RU (1) RU2750035C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201808820QA (cg-RX-API-DMAC7.html)
WO (1) WO2017178521A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022506108A (ja) * 2018-10-23 2022-01-17 グリカルディアル ダイアグノスティクス エセ. エレ. グリコシル化ApoJに特異的な抗体およびその使用
JP2022510403A (ja) * 2018-12-05 2022-01-26 グリカルディアル ダイアグノスティクス エセ. エレ. 虚血傷害および虚血再灌流傷害の予防および/または治療のための方法および組成物
KR102158726B1 (ko) 2019-04-17 2020-09-22 한림대학교 산학협력단 Itpr3 유전자 업스트림의 유전자간 영역을 포함하는 지연성 허혈 진단용 dna 메틸화 마커 조성물
KR102281657B1 (ko) 2019-12-23 2021-07-26 한림대학교 산학협력단 지연성 허혈 진단을 위한 cdhr5 유전자 과메틸화 마커
KR102281644B1 (ko) 2019-12-23 2021-07-23 한림대학교 산학협력단 지연성 허혈 진단을 위한 insr 유전자 과메틸화 마커
KR102312534B1 (ko) 2019-12-31 2021-10-13 한림대학교 산학협력단 뇌척수액 유래 미토콘드리아 마커를 이용한 지연성 허혈 진단 방법
KR102318236B1 (ko) 2020-02-18 2021-10-26 한림대학교 산학협력단 혈중 코펩틴의 농도를 이용한 지연성 뇌허혈 진단 방법
KR102336507B1 (ko) 2020-02-21 2021-12-06 한림대학교 산학협력단 국소뇌산소포화도를 이용한 지연성 뇌허혈 진단 방법
KR102369155B1 (ko) 2020-07-07 2022-02-28 한림대학교 산학협력단 근적외선 분광분석법을 이용한 지연성 뇌허혈 진단 방법
KR102473349B1 (ko) 2020-09-11 2022-12-05 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 kifap3 유전자 과메틸화 마커
KR102496589B1 (ko) 2020-09-11 2023-02-03 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 vhl 유전자 과메틸화 마커
KR102473350B1 (ko) 2020-09-11 2022-12-05 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 racgap1 유전자 과메틸화 마커
KR102473348B1 (ko) 2020-09-11 2022-12-05 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 kif3a 유전자 과메틸화 마커
KR102477500B1 (ko) 2020-09-15 2022-12-14 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 oprm1 유전자 과메틸화 마커
KR102477501B1 (ko) 2020-09-15 2022-12-14 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 alb 유전자 저메틸화 마커
KR102477502B1 (ko) 2020-09-15 2022-12-14 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 il5 유전자 저메틸화 마커
KR102466956B1 (ko) 2020-11-05 2022-11-11 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 dapk1 바이오마커
KR102398533B1 (ko) 2020-11-05 2022-05-13 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 뇌척수액 마이토파지 마커
KR102398534B1 (ko) 2020-11-05 2022-05-13 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 bnip3l 바이오마커
KR102470789B1 (ko) 2020-11-05 2022-11-25 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 pink1 바이오마커
CN113462744B (zh) * 2021-05-24 2023-06-23 中国药科大学 N-乙酰葡萄糖胺作为标志物在制备诊断缺血性脑中风试剂中的应用
KR102865129B1 (ko) 2021-08-06 2025-09-26 에이치앤비지노믹스 주식회사 지능형 오믹스 기반 개인별 맞춤형 복잡질환 발병 위험도 정보 제공 방법 및 장치

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140045A (en) 1995-03-10 2000-10-31 Meso Scale Technologies Multi-array, multi-specific electrochemiluminescence testing
CA2301634A1 (en) * 1997-07-15 1999-01-28 Pradeep Ghosh Determining alcohol intake using sialic acid/apo j
US6197599B1 (en) 1998-07-30 2001-03-06 Guorong Chin Method to detect proteins
WO2005107491A2 (en) * 2004-05-05 2005-11-17 Northeastern University Multi-lectin affinity chromatography and uses thereof
CN102695716B (zh) * 2009-07-14 2016-03-02 独立行政法人产业技术综合研究所 肝病病情指标糖链标记物
ES2364169B1 (es) 2010-02-09 2012-07-10 CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (Titular al 50%) Uso de las isoformas de apo j como biomarcadores de lesión tisular.
EP2400304A1 (en) 2010-06-22 2011-12-28 Centro de Investigación Cooperativa En Biomateriales ( CIC biomaGUNE) Method for the characterization of intermolecular interactions
JP2012107932A (ja) 2010-11-16 2012-06-07 Mitsubishi Chemicals Corp Clusterin蛋白質による脳梗塞の検査方法
ES2907068T3 (es) 2015-04-30 2022-04-21 Idexx Lab Inc Detección específica de isoformas de clusterina
CN107957498A (zh) * 2016-10-18 2018-04-24 厦门德馨尚品医疗科技有限公司 一种含有载脂蛋白j的试剂盒及其在临床诊断中的应用

Also Published As

Publication number Publication date
CN109154620B (zh) 2022-03-08
AU2017251355A1 (en) 2018-11-08
EP3232200A1 (en) 2017-10-18
MA44658A (fr) 2019-02-20
WO2017178521A1 (en) 2017-10-19
KR102344344B1 (ko) 2021-12-28
BR112018070971A2 (pt) 2019-01-29
KR20190008216A (ko) 2019-01-23
EP3443353A1 (en) 2019-02-20
RU2018139780A (ru) 2020-05-12
ES2979390T3 (es) 2024-09-25
US11486884B2 (en) 2022-11-01
JP7075894B2 (ja) 2022-05-26
RU2018139780A3 (cg-RX-API-DMAC7.html) 2020-07-24
EP3443353B1 (en) 2024-03-13
RU2750035C2 (ru) 2021-06-21
CA3020666A1 (en) 2017-10-19
IL262245B (en) 2021-03-25
CN109154620A (zh) 2019-01-04
MX2018012580A (es) 2019-02-25
IL262245A (en) 2018-11-29
JP2019516966A (ja) 2019-06-20
US20190128900A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
SG11201809252YA (en) Methods for determining dpp3 and therapeutic methods
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201808192RA (en) Non-invasive diagnostic of non-alcoholic steatohepatitis
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201808242UA (en) Methods for inhibiting angiogenesis in a subject in need thereof
SG11201804506RA (en) Systems and methods for rendering multiple levels of detail
SG11202000444PA (en) Sequencing output determination and analysis with target-associated molecules in quantification associated with biological targets
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201807972YA (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201808762XA (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
SG11201408434QA (en) Targeted rna-seq methods and materials for the diagnosis of prostate cancer
SG11201901611YA (en) Methods for the identification, targeting and isolation of human dendritic cell (dc) precursors "pre-dc" and their uses thereof
SG11201408383SA (en) Methods of detecting diseases or conditions using circulating diseased cells
SG11201909048TA (en) Use of klk5 antagonists for treatment of a disease
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201810544WA (en) Detecting hematological disorders using cell-free dna in blood
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201908154RA (en) Improved immunogenicity assays
SG11201807501UA (en) Method and system for imaging
SG11201907199QA (en) Cancer treatment
SG11201906778RA (en) Improved methods for assessing risk of developing breast cancer
SG11201804597TA (en) Vaccination with mica/b alpha 3 domain for the treatment of cancer
SG11201900133WA (en) Adrenomedullin for assessing congestion in a subject with acute heart failure
SG11201811763SA (en) B-cell-mimetic cells